about
A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides.QuEChERS-based approach toward the analysis of two insecticides, methomyl and aldicarb, in blood and brain tissueA novel sulfur mustard (HD) vapor inhalation exposure system for accurate inhaled dose delivery.The CounterACT Research Network: basic mechanisms and practical applications.Assessing the therapeutic efficacy of oxime therapies against percutaneous organophosphorus pesticide and nerve agent challenges in the Hartley guinea pig.Efficacy of Recommended Prehospital Human Equivalent Doses of Atropine and Pralidoxime Against the Toxic Effects of Carbamate Poisoning in the Hartley Guinea Pig.Evaluation of HemogloBind™ treatment for preparation of samples for cholinesterase analysis.Dramatic differences in organophosphorus hydrolase activity between human and chimeric recombinant mammalian paraoxonase-1 enzymes.A gas chromatographic-mass spectrometric approach to examining stereoselective interaction of human plasma proteins with soman.Direct detection of stereospecific soman hydrolysis by wild-type human serum paraoxonase.Synthesis and Storage Stability of DiisopropylfluorophosphateKinetic analysis of oxime-assisted reactivation of human, Guinea pig, and rat acetylcholinesterase inhibited by the organophosphorus pesticide metabolite phorate oxon (PHO).Toxicity and median effective doses of oxime therapies against percutaneous organophosphorus pesticide and nerve agent challenges in the Hartley guinea pig.Evaluating the broad-spectrum efficacy of the acetylcholinesterase oximes reactivators MMB4 DMS, HLö-7 DMS, and 2-PAM Cl against phorate oxon, sarin, and VX in the Hartley guinea pigAcute toxicity of phorate oxon by oral gavage in the Sprague-Dawley ratSupporting Fundamental Chemical Toxicology Research To Inform Medical Countermeasure Developments: The National Institutes of Health Chemical Countermeasures Research ProgramScreening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status EpilepticusNational Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)-August 6/7, 2019
P50
Q34628506-D44D4A5F-29EE-49C1-8BB2-C5839CADEECEQ34870820-2A3E50C2-A78F-43D5-807F-729EC8BD9671Q35020083-260C865E-360B-4EA3-B72B-1AD06E516CA7Q35173506-B85DC058-61EC-4789-84DE-1847C15F0C8DQ36561465-708B3A75-FCA3-4465-8A9F-DF475F59DE17Q36892707-6E87EB2F-7FB8-43F6-B1D6-86314BB9678DQ37707891-3F486675-6F9A-4FD3-9BF5-28D9C3FF6FD3Q39797833-C69BBE74-A435-42D7-A262-6510D135A281Q40124683-CB406F1B-33A0-4327-BB1C-7FE27E5209C1Q40244124-F237A3BC-DE8F-4676-B2B8-B4E16E043041Q40850466-13F76E27-F907-4868-B2D7-501B530C35EBQ51767129-D9E39E46-919B-4AAB-9695-48E873743DA9Q53059455-E43736DC-C723-485A-9E9E-44EABB37076FQ57095530-0B71870B-613C-4B39-8516-4734569ECE99Q88880685-04A69441-7C68-4F38-B772-04858342DF51Q90500931-C6D7D2D1-3872-4893-87C6-A9A15AA0B257Q91547850-6D86CA75-2477-44AB-9AB0-A74D1F492BCDQ92104551-058D5315-E393-4E75-B243-7ACE8F5F6EE4
P50
description
investigador
@es
researcher
@en
name
David T Yeung
@en
David T Yeung
@nl
type
label
David T Yeung
@en
David T Yeung
@nl
prefLabel
David T Yeung
@en
David T Yeung
@nl
P108
P108
P31
P496
0000-0001-5692-0170